3. If the patient develops a uterine contraction abnormality as defined below, either terbutaline, 0.25 mg IV or SQ or MgSO4 intravenous infusion may be administered as necessary. If such abnormalities are encountered during oxytocin administration, the infusion will be discontinued and the same treatment may be utilized.